Skip to main content
. Author manuscript; available in PMC: 2010 Sep 7.
Published in final edited form as: Br J Haematol. 2009 Jan 8;145(1):45–58. doi: 10.1111/j.1365-2141.2008.07562.x

Fig 6. Event-free and overall survival of previously untreated MM patients with CASP2high or CASP2low MMC and BIRC5present or BIRC5absent MMC.

Fig 6

CASP2 and BIRC5 gene expressions were assayed in purified MMC with U133 Plus 2.0 microarrays. (A) Event-free survival of MM patients with CASP2high or CASP2low MMC from HM series (85 versus 85 patients) and (B) from LR-TT2 series (172 versus 172 patients). (C) Overall survival of MM patients with BIRC5present or BIRC5absent MMC from HM series (45 versus 126 patients) and (D) from LR-TT2 series (41 versus 304 patients). The P-value was determined with a log-rank test.